Development of a facile antibody–drug conjugate platform for increased stability and homogeneity

New developments for antibody-drug conjugate-based therapeutic approaches

(2016) Bart ECG de Goeij et al.   CURRENT OPINION IN IMMUNOLOGY

Field Guide to Challenges and Opportunities in Antibody–Drug Conjugates for Chemists

(2015) Mallory R. Gordon et al.   BIOCONJUGATE CHEMISTRY

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

(2015) A. V. Yurkovetskiy et al.   CANCER RESEARCH

Platinum(II) as Bifunctional Linker in Antibody-Drug Conjugate Formation: Coupling of a 4-Nitrobenzo-2-oxa-1,3-diazole Fluorophore to Trastuzumab as a Model

(2015) Dennis C. J. Waalboer et al.   ChemMedChem

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

(2015) Ronald C. Elgersma et al.   MOLECULAR PHARMACEUTICS

Current ADC Linker Chemistry

(2015) Nareshkumar Jain et al.   PHARMACEUTICAL RESEARCH

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Statistical Modeling of the Drug Load Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug Conjugate

(2014) Michael T. Kim et al.   BIOCONJUGATE CHEMISTRY

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Improving the Therapeutic Index in Cancer Therapy by Using Antibody–Drug Conjugates Designed with a Moderately Cytotoxic Drug

(2014) Serengulam V. Govindan et al.   MOLECULAR PHARMACEUTICS

Methods for site-specific drug conjugation to antibodies

(2013) Christopher R Behrens et al.   mAbs

Designing immunoconjugates for cancer therapy

(2012) Serengulam V Govindan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase

(2010) Simone Jeger et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY